Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.04 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

living cell technologies ltd (LVCLF) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/9/14 - $0.08
52 Week Low
03/9/15 - $0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

living cell technologies ltd (LVCLF) Related Businessweek News

No Related Businessweek News Found

living cell technologies ltd (LVCLF) Details

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes cell therapies to treat diseases with high unmet clinical need worldwide. The company’s therapeutic candidates include DIABECELL, which is in late-stage clinical trials for the treatment of type 1 diabetes; and NTCELL, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson’s disease. It has a collaboration agreement with the Centre for Brain Research to identify neurodegenerative disease targets for clinical studies of NTCELL product. The company was founded in 1987 and is based in Auckland, New Zealand.

Founded in 1987

living cell technologies ltd (LVCLF) Top Compensated Officers

Chief Executive
Total Annual Compensation: A$79.7K
Co-Founder and Executive Director
Total Annual Compensation: A$126.6K
Head of Finance & Administration
Total Annual Compensation: A$184.0K
Compensation as of Fiscal Year 2014.

living cell technologies ltd (LVCLF) Key Developments

Living Cell Technologies Limited Reports Cash Flow Results for the Quarter Ended March 31, 2015

Living Cell Technologies Limited reported cash flow results for the quarter ended March 31, 2015. For the quarter, the company reported net operating cash outflows of AUD 695,388 compared to AUD 274,006 in the previous quarter.

Bob Elliott to Step Down from Living Cell Technologies Limited as Executive Director, Clinical Research and Innovation, Effective from February 27, 2015

Living Cell Technologies Limited announced that co-founder Emeritus Professor Bob Elliott will step down from the position of Executive Director, Clinical Research and Innovation with effect from 27 February 2015. He will continue as a board director of LCT and chairman of Diatranz Otsuka Limited. He will pursue a number of projects in which he has a personal interest.

Living Cell Technologies Limited and Centre for Brain Research Collaborate to Develop Novel Neurological Treatments

Living Cell Technologies Limited has formed collaboration with the Centre for Brain Research to identify additional neurodegenerative disease targets for clinical studies of LCT's NTCELL product.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LVCLF:US $0.04 USD 0.00

LVCLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LVCLF.
View Industry Companies

Industry Analysis


Industry Average

Valuation LVCLF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIVING CELL TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at